BRPI0811486A2 - Tratamento de doença cardiovascular e dislipidemia usando inibidores de fosfolipase a2 secretória (spla2) e terapias de combinação com inibidor de spla2 - Google Patents

Tratamento de doença cardiovascular e dislipidemia usando inibidores de fosfolipase a2 secretória (spla2) e terapias de combinação com inibidor de spla2

Info

Publication number
BRPI0811486A2
BRPI0811486A2 BRPI0811486-2A2A BRPI0811486A BRPI0811486A2 BR PI0811486 A2 BRPI0811486 A2 BR PI0811486A2 BR PI0811486 A BRPI0811486 A BR PI0811486A BR PI0811486 A2 BRPI0811486 A2 BR PI0811486A2
Authority
BR
Brazil
Prior art keywords
spla2
dislipidemia
inhibitors
cardiovascular disease
combination therapies
Prior art date
Application number
BRPI0811486-2A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Joaquim Trias
Colin Hislop
Paul Truex
Bernardine Fraser
Debra Odinik
Scott Chadwick
Kenneth Gould
Patrick Eacho
Marian Mosior
Original Assignee
Anthera Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthera Pharmaceuticals Inc filed Critical Anthera Pharmaceuticals Inc
Publication of BRPI0811486A2 publication Critical patent/BRPI0811486A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0811486-2A2A 2007-05-03 2008-05-02 Tratamento de doença cardiovascular e dislipidemia usando inibidores de fosfolipase a2 secretória (spla2) e terapias de combinação com inibidor de spla2 BRPI0811486A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US91591007P 2007-05-03 2007-05-03
US96959107P 2007-08-31 2007-08-31
US87486907A 2007-10-18 2007-10-18
PCT/US2008/062577 WO2008137803A1 (en) 2007-05-03 2008-05-02 Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies

Publications (1)

Publication Number Publication Date
BRPI0811486A2 true BRPI0811486A2 (pt) 2014-09-30

Family

ID=39943969

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0811486-2A2A BRPI0811486A2 (pt) 2007-05-03 2008-05-02 Tratamento de doença cardiovascular e dislipidemia usando inibidores de fosfolipase a2 secretória (spla2) e terapias de combinação com inibidor de spla2

Country Status (8)

Country Link
EP (1) EP2154958A4 (enExample)
JP (1) JP2010526152A (enExample)
CN (1) CN101742907A (enExample)
AU (1) AU2008247451A1 (enExample)
BR (1) BRPI0811486A2 (enExample)
CA (1) CA2686157A1 (enExample)
EA (1) EA200971020A1 (enExample)
WO (1) WO2008137803A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102271507A (zh) * 2009-01-08 2011-12-07 安塞拉制药有限公司 分泌型磷脂酶a2(spla2)抑制剂和烟酸药物组合物以及治疗心血管疾病和血脂异常的方法
RU2483707C1 (ru) * 2012-05-04 2013-06-10 Лира Талгатовна Гильмутдинова Способ санаторной терапии больных с метаболическим синдромом и артериальной гипертензией с применением сульфидных ванн
CN115040508A (zh) * 2022-07-28 2022-09-13 上海市同仁医院 吲哚-3-乙醛在制备新型抗肥胖活性制剂中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
ID27812A (id) * 1998-05-01 2001-04-26 Lilly Co Eli ESTER PENGHAMBAT sPLA2
AU2001236440A1 (en) * 2000-01-25 2001-08-07 Eli Lilly And Company Method for the treatment of inflammation with spla2 inhibitors
WO2002008189A1 (en) * 2000-07-24 2002-01-31 The University Of Queensland Compounds and inhibitors of phospholipases
TWI314457B (enExample) * 2001-03-19 2009-09-11 Shionogi & Co
US20060094693A1 (en) * 2004-09-21 2006-05-04 Point Therapeutics, Inc. Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions
EP1960356A2 (en) * 2005-11-03 2008-08-27 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors

Also Published As

Publication number Publication date
CA2686157A1 (en) 2008-11-13
AU2008247451A1 (en) 2008-11-13
EA200971020A1 (ru) 2010-10-29
EP2154958A1 (en) 2010-02-24
JP2010526152A (ja) 2010-07-29
CN101742907A (zh) 2010-06-16
EP2154958A4 (en) 2011-05-04
WO2008137803A1 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
CY2019009I1 (el) Αναστολεις πρωτεϊνικων κινασων
CY2016041I2 (el) Αναστολεις κινασης τυροσινης bruton
EP2051707A4 (en) Plasma kallikrein INHIBITORS
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
DK1940839T3 (da) Pyridopyrimidione Inhibitors of P13Ka
IL186912A0 (en) Inhibitors of cytosolic phospholipase a2
CR10831A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
HRP20150003T1 (xx) Sastavi inhibitora dpp-iv
EP2166846A4 (en) JANUS KINASE INHIBITORS
EP2231143A4 (en) JANUS KINASE INHIBITORS
EP2007383A4 (en) HEMMER OF PROTEIN PRENYL TRANSFERASES
EP2278969A4 (en) JANUS KINASE INHIBITORS
EP2299816A4 (en) JANUS KINASE INHIBITORS
DK2099447T3 (da) Imidazotriaziner og imidazopyrimidiner som kinaseinhibitorer
DK2379600T3 (da) Antistoffer mod tissue factor pathway inhibitor
BRPI0906735A2 (pt) Terapia de combinação que compreende inibidores de sglt e inibidores de dpp4
EP2170073A4 (en) SELECTIVE INHIBITORS FOR CYCLINE-RELATED KINASES
PT1931350E (pt) Administração de inibidores de dipeptidil peptidase
EP2310384A4 (en) JANUS KINASE INHIBITORS
EP1926485A4 (en) HIF-INHIBITORS
EP2456440A4 (en) Quinolinone PDE2 INHIBITORS
EP2200612A4 (en) JANUS KINASE INHIBITORS
EP2032141A4 (en) JANUS KINASE INHIBITORS
EP2316491A4 (en) CELL PROLIFERATION INHIBITORS

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.